Product image of Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202) supplied by GNH India

Influvac Tetra

Active Ingredient:
B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202
Origin:
EU

Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

B/Phuket/3073/2013-like virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredient in Influvac Tetra, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by the specified B virus strains in individuals for whom vaccination is recommended.

GNH India supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring quality assurance and regulatory compliance for global influenza vaccination programs through reliable cold‑chain logistics.

Manufacturer / TM Owner

Viatris Oy

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Influvac Tetra is a quadrivalent influenza vaccine used to prevent influenza infection caused by specific virus strains.

  • Prevention of influenza infection caused by influenza virus B/Phuket/3073/2013‑like strain: reduces the risk of illness in vaccinated individuals.
  • Prevention of influenza infection caused by influenza virus B/Austria/1359417/202 strain: reduces the risk of illness in vaccinated individuals.
  • Seasonal influenza prevention: provides broader protection against circulating influenza viruses during the flu season.

How It Works

  • Influvac Tetra contains inactivated viral antigens from the designated influenza B strains. After intramuscular or subcutaneous injection, the antigens are taken up by antigen‑presenting cells, stimulating B‑cell and T‑cell responses that lead to the production of neutralizing antibodies against the hemagglutinin proteins of the target viruses, thereby conferring protective immunity.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Low‑grade fever: transient temperature rise.
  • Headache: mild headache within 24‑48 hours.
  • Myalgia: muscle aches or soreness.
  • Fatigue: temporary tiredness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder.
  • Severe allergic reaction: hives, swelling of face or throat.
  • High fever: temperature >39°C persisting more than 48 hours.
  • Seizures: rare convulsive episodes.
  • Acute respiratory distress: difficulty breathing post‑vaccination.

Precautions & Warnings

Before administering Influvac Tetra, consider the following precautions:

  • Severe allergy: avoid in persons with known hypersensitivity to any vaccine component.
  • Pregnancy: consult a healthcare provider; vaccination may be given if benefits outweigh potential risks.
  • Immunocompromised patients: vaccine may be less effective; assess individual benefit.
  • Age restriction: not recommended for children younger than 6 months.
  • Acute illness: defer vaccination if the individual has moderate or severe fever or infection.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Influvac Tetra may interact with other medicines or vaccines as follows:

Major Interactions (Avoid)

  • Live attenuated vaccines: avoid co‑administration with live influenza vaccines.
  • Immunoglobulin therapy: may reduce vaccine efficacy if given concurrently.
  • Antiviral agents (e.g., oseltamivir) within 48 hours: may interfere with immune response.

Moderate Interactions (Monitor Closely)

  • Other vaccines: can be administered at separate sites, monitor for additive local reactions.
  • Immunosuppressive drugs: may diminish antibody response; consider serologic testing.

Frequently Asked Questions

Influvac Tetra is a quadrivalent influenza vaccine designed to protect against influenza infection caused by the B/Phuket/3073/2013‑like and B/Austria/1359417/202 virus strains. It is administered to individuals for whom seasonal flu vaccination is recommended, helping to reduce the incidence and severity of flu illness.

The vaccine contains inactivated antigens from the specified influenza B viruses. When injected, these antigens stimulate the immune system to produce neutralizing antibodies against the viral hemagglutinin proteins, establishing immunity that can prevent infection or lessen disease severity if exposure occurs.

The dosage and schedule of Influvac Tetra are determined by the prescribing healthcare professional based on age, health status, and local immunization guidelines. The prescriber will decide the appropriate volume and timing for each individual patient.

Safety data for Influvac Tetra in pregnancy are limited. Healthcare providers may consider vaccination if the potential benefits outweigh any theoretical risks. The vaccine is not known to be harmful during breastfeeding, but a clinician should be consulted before administration.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Influvac Tetra is a quadrivalent vaccine that specifically includes the B/Phuket and B/Austria strains, offering protection against these circulating B lineages. Compared with trivalent formulations, it provides broader coverage of influenza B viruses, which can be advantageous in seasons where both B lineages co‑circulate.

Influvac Tetra must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Proper cold‑chain management is essential to maintain vaccine potency until administration.

The vaccine is supplied as an injectable solution and is given by a trained healthcare professional via intramuscular or subcutaneous injection, typically in the deltoid muscle of the upper arm. The injection site should be cleaned with an appropriate antiseptic before administration.

Serious adverse events are rare but can include anaphylaxis, Guillain‑Barré syndrome, severe allergic reactions, high fever, seizures, and acute respiratory distress. Any of these symptoms after vaccination require immediate medical evaluation.

Individuals with a known severe allergy to any component of the vaccine, those who have experienced a previous severe reaction to an influenza vaccine, children under 6 months of age, and persons with acute moderate or severe illness should not receive Influvac Tetra until evaluated by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT